▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #221 by analyst upside · 2026-08-12
ATYR
aTyr Pharma, Inc.
Healthcare · Market Cap $52M · P/E 0x
ANALYST PRICE TARGET
+435.0%
implied upside to consensus target
Current Price $0.53
Consensus Target $2.86
Bull Target $7.0
Bear Target $1.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
2
Hold
4
Sell
0
52-Week Low $0.4
52-Week High $6.5
YTD Return -29.6%
FUNDAMENTALS
Market Cap $52M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.63
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.4
52-Week High $6.5
Current Price $0.53
Bear Target $1.0
Bull Target $7.0
● Now $0.53 ● Target $2.86
TRADING DATA
Avg Volume 2.5M
YTD Return -29.6%
Analyst Count 7
Consensus Buy
Upside to Target +435.0%
Last Updated 2026-08-12

ANALYST SUMMARY

aTyr Pharma, Inc. (ATYR) is currently trading at $0.53 with a Wall Street consensus price target of $2.86, implying potential upside of 435.0% over the next 12 months. 7 analysts currently cover ATYR, with a consensus rating of Buy - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $7.0, while the most cautious has a target of $1.0.

ATYR operates in the Healthcare sector with a market capitalisation of $52M. The stock is down 29.6% year-to-date and is currently trading near the lower end of its 52-week range of $0.4 – $6.5.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

VXRT +511.6%
Vaxart, Inc.
$132M · P/E 3.2x · Buy
ATNM +530.4%
Actinium Pharmaceuticals, Inc.
$25M · P/E 2.3x · Buy
XTNT +321.9%
Xtant Medical Holdings, Inc.
$45M · P/E 32.0x · Strong Buy
FBIO +321.5%
Fortress Biotech, Inc.
$87M · P/E 0.8x · Buy
PLX +352.7%
Protalix BioTherapeutics, Inc.
$196M · P/E 12.8x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ATYR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Freedom Broker ↑ Upgrade
Hold → Buy 2026-05-20 Building track record
RBC Capital - Reiterated
Sector Perform → Sector Perform 2025-11-07 Building track record
Wells Fargo ↓ Downgrade
Overweight → Equal-Weight 2025-09-16 Building track record
RBC Capital ↓ Downgrade
Outperform → Sector Perform 2025-09-16 Building track record
HC Wainwright & Co. ↓ Downgrade
Buy → Neutral 2025-09-15 31% win rate (48 calls)
Leerink Partners ↓ Downgrade
Outperform → Market Perform 2025-09-15 29% win rate (7 calls)
Jones Trading ↓ Downgrade
Buy → Hold 2025-09-15 57% win rate (14 calls)
Cantor Fitzgerald ↓ Downgrade
Overweight → Neutral 2025-09-15 40% win rate (10 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
23
out of 100
Coverage depth
16/30
Consensus clarity
0/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →